ESPERITE's shareholders approved the external financing of up to EUR 13 million

 

Esperite N.V. (Euronext: ESP, "Esperite") announces that at its Extraordinary General Meeting of shareholders ("EGM"), held on Friday 21 April 2017, all proposals were unanimously approved.

Shareholders unanimously approve the issuance of further tranches of convertible notes (with share subscription warrants attached) to European Select Growth Opportunities Fund 

This means that Esperite will now be able to proceed with the recently announced external financing of up to EUR 13 million and the issuance of further tranches of convertible notes (with share subscription warrants attached) to European Select Growth Opportunities Fund.

As announced previously, the proceeds shall be used to support Esperite's commercial activities and development of innovative technologies in the field of genetics for Genoma and regenerative medicine for Cryo-Save and Cell Factory. 

The presentation slides from today's EGM can be downloaded from Esperite's website (www.esperite.com).

Note

About ESPERITE N.V.

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?